Literature DB >> 8599205

HIV-1 infection of cultured human adult oligodendrocytes.

A V Albright1, J Strizki, J M Harouse, E Lavi, M O'Connor, F González-Scarano.   

Abstract

The mechanism through which HIV-1 causes HIV dementia (HIVD) is not well understood. Myelin pallor is a common pathological finding in HIVD and could be explained by a direct infection of oligodendrocytes or interaction with HIV-1 gp 120. To determine if oligodendrocytes could be infected by HIV-1, we purified oligodendrocytes from adult human brain tissues obtained from temporal lobe resections. These cells were exposed to HIV-1 and infectivity was assayed by detection of p24gag antigen, PCR amplification, and cocultivation with CD4+ cells. These results indicate that HIV-1(IIIB and BaL) and one of four primary isolates tested can infect oligodendrocytes, resulting in the production of infectious virus. Furthermore, in an experiment that mimics a potential in vivo scenario, infected microglia were able to transmit virus to oligodendrocytes in a trans-well culture system. These experiments indicate that oligodendrocyte infection should be considered in studying the pathophysiology of HIVD.

Entities:  

Mesh:

Year:  1996        PMID: 8599205     DOI: 10.1006/viro.1996.0108

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  24 in total

Review 1.  Virus receptors in the human central nervous system.

Authors:  B Schweighardt; W J Atwood
Journal:  J Neurovirol       Date:  2001-06       Impact factor: 2.643

2.  Functional interactions between C/EBP, Sp1, and COUP-TF regulate human immunodeficiency virus type 1 gene transcription in human brain cells.

Authors:  C Schwartz; P Catez; O Rohr; D Lecestre; D Aunis; E Schaeffer
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  CXCR-4 (Fusin), a co-receptor for the type 1 human immunodeficiency virus (HIV-1), is expressed in the human brain in a variety of cell types, including microglia and neurons.

Authors:  E Lavi; J M Strizki; A M Ulrich; W Zhang; L Fu; Q Wang; M O'Connor; J A Hoxie; F González-Scarano
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

Review 4.  Role of microglia in central nervous system infections.

Authors:  R Bryan Rock; Genya Gekker; Shuxian Hu; Wen S Sheng; Maxim Cheeran; James R Lokensgard; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 5.  HIV-1 infection alters energy metabolism in the brain: Contributions to HIV-associated neurocognitive disorders.

Authors:  Bianca Cotto; Kalimuthusamy Natarajanseenivasan; Dianne Langford
Journal:  Prog Neurobiol       Date:  2019-05-18       Impact factor: 11.685

6.  Chemokine receptor utilization by human immunodeficiency virus type 1 isolates that replicate in microglia.

Authors:  J T Shieh; A V Albright; M Sharron; S Gartner; J Strizki; R W Doms; F González-Scarano
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

7.  Effects of HIV-1 Tat on oligodendrocyte viability are mediated by CaMKIIβ-GSK3β interactions.

Authors:  Shiping Zou; Joyce M Balinang; Jason J Paris; Kurt F Hauser; Babette Fuss; Pamela E Knapp
Journal:  J Neurochem       Date:  2019-03-15       Impact factor: 5.372

8.  Oligodendrocyte-specific expression of human immunodeficiency virus type 1 Nef in transgenic mice leads to vacuolar myelopathy and alters oligodendrocyte phenotype in vitro.

Authors:  Fatiha Radja; Denis G Kay; Steffen Albrecht; Paul Jolicoeur
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Contribution of CNS cells in NeuroAIDS.

Authors:  Ashish Swarup Verma; Udai Pratap Singh; Premendra Dhar Dwivedi; Anchal Singh
Journal:  J Pharm Bioallied Sci       Date:  2010-10

10.  Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates.

Authors:  A V Albright; J T Shieh; T Itoh; B Lee; D Pleasure; M J O'Connor; R W Doms; F González-Scarano
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.